Context Therapeutics, Inc. CNTX 深 滬
已收盤 02-06 16:00:00 美东时间
2.28
+0.020
+0.88%
華盛通- 最 高2.3296
- 今 開2.27
- 成交量 230.25万股
- 最 低 2.02
- 昨 收 2.26
- 總市值 2.09亿
- 52周最高 2.85
- 市盈率 靜 --
- 換手率 2.51%
- 52周最低 0.49
- 委 比 -67.91%
- 總股本 9187.92万
- 歷史最高 10.87
- 量 比 1.08
- 振 幅 13.70%
- 歷史最低 0.47
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7
Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
2025-12-22 20:25
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
2025-11-06 19:52
Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses of $(0.22) per share
2025-11-06 06:02
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Inc. announced its participation in two upcoming investor conferences: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, November 10-12, 2025, featuring a Fireside Chat on November 10 at 3:00 PM ET and 1x1 meetings, and the Stifel 2025 Healthcare Conference in New York, November 11-13, 2025, with a presentation on November 12 at 10:00 AM ET and 1x1 meetings. A live webcast will be available on the Company’...
2025-10-28 11:30
Context Therapeutics Regains Nasdaq Compliance
The latest update is out from Context Therapeutics ( ($CNTX) ). Context Therape...
2025-10-21 06:25
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
2025-10-17 09:58
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
2025-10-16 20:40
Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced two posters will
2025-10-06 19:38
